Press "Enter" to skip to content

Indian Firm Pulls Out Heart Drug From US Amid Cancer Risk Probes

“}var y='”;$(“#main_score_strip_top”).html(y),set_score_slider_style()}else $(“#top_strip_cricket_widget”).html(“”),”undefined”!=typeof updateTopScoreWidgetNews18&&clearInterval(updateTopScoreWidgetNews18),console.log(“no live match in progress”)},error:function(e){console.log(“error in live score widget”),$(“#top_strip_cricket_widget”).html(“”)}})} function get_live_team_scores(e,s,i){var e=get_ipl_teams_short(e),t=s,i=i,a=”https://images.news18.com/static_news18/ibnlive/pix/ibnhome/cricketnext/microsite/teamsicon/”,r=a+e.toLowerCase()+”.png”,n=”,c=t.length;if(c>0){for(var o=1,v=””,l=0;c>l;l++){var m=t[l].scores,p=t[l].wickets,f=t[l].overs,g=t[l].active;if(1==g)var d=”“,_=”“;else d=””,_=””;if(2==o)var b=” & “;else var b=””;”test”==i?(v=v+” “+b+d+m+”/”+p+_,o+=1):(v=v+” “+d+m+”/”+p+”(“+f+”)”+_+b,o+=1)}var h=d+e+_;h=’

‘+n+h+v+”

“}else h=’

‘+n+e+’ (YET TO BAT)

‘;return h} function convertToSlug(e){return e.replace(” (W)”,””).replace(” (C)”,””).toLowerCase().replace(/[^w ]+/g,””).replace(/ +/g,”-“)} function get_ipl_teams_short(a){var r=new Array;return r.Kolkata=”KKR”,r.KOL=”KKR”,r.MUM=”MI”,r.Mumbai=”MI”,r.HYD=”SRH”,r.Hyderabad=”SRH”,r.PUN=”RPS”,r.Punjab=”KXIP”,r.PNJ=”KXIP”,r.Bangalore=”RCB”,r.BLR=”RCB”,r.Delhi=”DD”,r.DEL=”DD”,r.Pune=”RPS”,r.Gujarat=”GL”,r.GUJ=”GL”,r.TBC=”TBC”,a in r?r[a]:a} var updateTopScoreWidgetNews18=setInterval(function(){news18_top_widget_live_scores() }, 20000);});

“Test results from Hetero Labs show the amount of NDMA found in its valsartan active pharmaceutical ingredient (API) exceeds acceptable levels; although it is generally lower than the amount discovered in the API manufactured by Zhejiang,” the FDA said.

Reuters

Updated:August 11, 2018, 6:23 PM IST

Image for representation purpose only.

Loading…

Mumbai: A unit of Hetero Drugs is recalling some batches of the blood pressure and heart medicine valsartan in the United States, a notice on the U.S. regulator’s website said, amid a wider probe into cancer risks associated with the drug.

At least a dozen companies around the world have pulled specific batches of valsartan from the market since early July, when regulators said valsartan made by the Chinese supplier Zhejiang Huahai Pharmaceuticals had been found to contain a probable human carcinogen, N-nitrosodimethylamine (NDMA).

The notice from the U.S. Food and Drug Administration (FDA) said Hetero was found to be using a similar manufacturing process to China’s Zhejiang Huahai for valsartan.

“Test results from Hetero Labs show the amount of NDMA found in its valsartan active pharmaceutical ingredient (API) exceeds acceptable levels; although it is generally lower than the amount discovered in the API manufactured by Zhejiang,” the FDA said.
Hetero declined to comment, a spokesman said.

The company, among India’s top 15 drugmakers and one of the world’s largest suppliers of HIV/AIDS drugs, sells valsartan in the United States through its unit Camber Pharmaceuticals, which is recalling the drug as a “precautionary measure,” the FDA notice said.

It added that Camber had not received any reports of adverse events related to the drug.

Calls to New Jersey-based Camber went unanswered on Saturday, outside of regular working hours.

INDIA IMPORTS

Valsartan was originally developed by the Swiss firm Novartis and sold under the name Diovan, but it is now off patent and is used in several generic medicines made by companies around the world.

Hetero’s website says the company has more than 30 manufacturing plants around the world.

India has temporarily suspended imports of medicines from China that contain valsartan, K. Bangarurajan, a joint drugs controller at the Central Drugs Standard Control Organization, told Reuters on Saturday.

Imports from elsewhere continue, he said.

“Not all imports have been blocked,” he said, adding that the action was taken after FDA posted a notice about cancer links to valsartan last month.

European regulators said on Friday that a second Chinese contract manufacturer, Zhejiang Tianyu, had produced valsartan with the cancer-causing chemical.

NDMA is classified as a probable human carcinogen. Based on results from laboratory tests, it may cause cancer with long-term use.

China and India supply more than two-thirds of all active drug ingredients used in medicines, industry experts estimate.

Also Watch

‘;
$(‘#first-watch-box’).html(response+titleHeading);
}
},
error: function(xhr, ajaxOptions, thrownError) {
console.log(‘Something went wrong..’);
}
});
}

var playWatchVideos = false;
$(window).scroll(function() {
var ividFirstScroll = $(‘.alsowatch’).offset().top – 100;
var tagsScroll = $(‘.tag’).offset().top;
var topOffsetIvid = $(window).scrollTop();
var topIviddistance = topOffsetIvid – ividFirstScroll;
var finalScrollEnd = ividFirstScroll + 650;
var holaPlayDivId = $(‘div.video-js’).attr(‘id’);
var holaPlayerObj = videojs(holaPlayDivId);
if(topOffsetIvid>ividFirstScroll && topOffsetIvidfinalScrollEnd && playWatchVideos==true) {
holaPlayerObj.pause();
playWatchVideos=false;
}

});

| Edited by: Huma Tabassum

Read full article

Loading…

Source: News18